MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2354-2368

  Zhu, Guoqi ^a   Li, Junyao ^a   He, Ling ^a   Wang, Xuncui ^a   Hong, Xiaoqi ^b  

^a ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM; MEMANTINE; 1 METHYL 4 PHENYLPYRIDINIUM; ANTIPARKINSON AGENT; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NTRK2 PROTEIN, MOUSE; PROTEIN TYROSINE KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CALCIUM SIGNALING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HIPPOCAMPUS; IN VITRO STUDY; LONG TERM DEPRESSION; LONG TERM MEMORY; LONG TERM POTENTIATION; LOW DRUG DOSE; MALE; MEMORY DISORDER; MOUSE; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MEMORY DISORDERS; METABOLISM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION; SYNAPSE; TIME FACTOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM SIGNALING; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HIPPOCAMPUS; IN VITRO TECHNIQUES; MALE; MEMANTINE; MEMBRANE GLYCOPROTEINS; MEMORY DISORDERS; MEMORY, LONG-TERM; MICE, INBRED C57BL; NEURONAL PLASTICITY; PARKINSONIAN DISORDERS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SYNAPSES; TIME FACTORS;

EID: 84924544578     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13061     Document Type: Article

References (61)

1. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8: 613-618.
2. Aicardi G, Argilli E, Cappello S, Santi S, Riccio M, Thoenen H, et al. (2004). Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 101: 15788-15792.
3. Akaneya Y, Tsumoto T, Hatanaka H, (1996). Brain-derived neurotrophic factor blocks long-term depression in rat visual cortex. J Neurophysiol 76: 4198-4201.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170, 1676-1705.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK, (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138: 155-175.
7. Bezard E, Imbert C, Gross CE, (1998). Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 9: 71-90.
8. Calabresi P, Castrioto A, Di Filippo M, Picconi B, (2013). New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol 12: 811-821.
9. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA, (2003). Parkinson's disease is associated with hippocampal atrophy. Mov Disord 18: 784-790.
10. Chiasserini D, Tozzi A, de Iure A, Tantucci M, Susta F, Orvietani PL, et al. (2011). Mortalin inhibition in experimental Parkinson's disease. Mov Disord 26: 1639-1647.
11. Collingridge GL, Peineau S, Howland JG, Wang YT, (2010). Long-term depression in the CNS. Nat Rev Neurosci 11: 459-473.
12. Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, et al. (2012). Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 135 (Pt 6): 1884-1899.
13. Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J, (2012). The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. Exp Neurol 233: 513-522.
14. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. (2010). Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 969-977.
15. Erickson JT, Brosenitsch TA, Katz DM, (2001). Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J Neurosci 21: 581-589.
16. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. (2011). Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 108: 3017-3022.
17. Filipov NM, Norwood AB, Sistrunk SC, (2009). Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 20: 713-717.
18. Frankiewicz T, Parsons CG, (1999). Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38: 1253-1259.
19. Fredriksson A, Eriksson P, Archer T, (1997). MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J Neural Transm 104: 579-592.
20. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O, (1994). Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 91: 5104-5108.
21. Fumagalli F, Racagni G, Riva MA, (2006). Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 6: 95-104.
22. Gartner A, Staiger V, (2002). Neurotrophin secretion from hippocampal neurons evoked by long-term-potentiation-inducing electrical stimulation patterns. Proc Natl Acad Sci U S A 99: 6386-6391.
23. Grunblatt E, Mandel S, Maor G, Youdim MB, (2001). Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78: 1-12.
24. Hardingham GE, Fukunaga Y, Bading H, (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414.
25. He YY, Zhang XY, Yung WH, Zhu JN, Wang JJ, (2013). Role of BDNF in central motor structures and motor diseases. Mol Neurobiol 48: 783-793.
26. Huang F, Chotiner JK, Steward O, (2007). Actin polymerization and ERK phosphorylation are required for Arc/Arg3.1 mRNA targeting to activated synaptic sites on dendrites. J Neurosci 27: 9054-9067.
27. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, et al. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232.
28. Ikegaya Y, Ishizaka Y, Matsuki N, (2002). BDNF attenuates hippocampal LTD via activation of phospholipase C: implications for a vertical shift in the frequency-response curve of synaptic plasticity. Eur J Neurosci 16: 145-148.
29. Jarvik ME, Kopp R, (1967). An improved one-trial passive avoidance learning situation. Psychol Rep 21: 221-224.
30. Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM, (2008). Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 30: 243-245.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, et al. (2000). Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15: 613-626.
33. Kumura E, Kimura F, Taniguchi N, Tsumoto T, (2000). Brain-derived neurotrophic factor blocks long-term depression in solitary neurones cultured from rat visual cortex. J Physiol 524 (Pt 1): 195-204.
34. Lesemann A, Reinel C, Huhnchen P, Pilhatsch M, Hellweg R, Klaissle P, et al. (2012). MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Res 1457: 51-69.
35. Levivier M, Przedborski S, Bencsics C, Kang UJ, (1995). Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 15: 7810-7820.
36. MacDonald PA, MacDonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost JS, et al. (2011). The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 134 (Pt 5): 1447-1463.
37. Maharana C, Sharma KP, Sharma SK, (2013). Feedback mechanism in depolarization-induced sustained activation of extracellular signal-regulated kinase in the hippocampus. Sci Rep 3: 1103.
38. Mandelman SD, Grigorenko EL, (2012). BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav 11: 127-136.
39. Martin MG, Perga S, Trovo L, Rasola A, Holm P, Rantamaki T, et al. (2008). Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro. Mol Biol Cell 19: 2101-2112.
40. Martinez TN, Greenamyre JT, (2012). Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal 16: 920-934.
41. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al. (2010). Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176: 870-880.
42. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
43. Miah IP, Olde Dubbelink KT, Stoffers D, Deijen JB, Berendse HW, (2012). Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy. Eur J Neurol 19: 510-516.
44. Minichiello L, (2009). TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10: 850-860.
45. Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M, (2002). Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 36: 121-137.
46. Montalbano A, Baj G, Papadia D, Tongiorgi E, Sciancalepore M, (2013). Blockade of BDNF signaling turns chemically-induced long-term potentiation into long-term depression. Hippocampus 23: 879-889.
47. Moriguchi S, Yabuki Y, Fukunaga K, (2012). Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. J Neurochem 120: 541-551.
48. Nagahara AH, Tuszynski MH, (2011). Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10: 209-219.
49. Novkovic T, Mittmann T, Manahan-Vaughan D, (2014). BDNF contributes to the facilitation of hippocampal synaptic plasticity and learning enabled by environmental enrichment. Hippocampus 25: 1-15.
50. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
51. Poletti M, Bonuccelli U, (2013). Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Ther Adv Psychopharmacol 3: 101-113.
52. Porritt MJ, Batchelor PE, Howells DW, (2005). Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 192: 226-234.
53. Rosch H, Schweigreiter R, Bonhoeffer T, Barde YA, Korte M, (2005). The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus. Proc Natl Acad Sci U S A 102: 7362-7367.
54. Selcher JC, Weeber EJ, Christian J, Nekrasova T, Landreth GE, Sweatt JD, (2003). A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. Learn Mem 10: 26-39.
55. Shohamy D, Myers CE, Hopkins RO, Sage J, Gluck MA, (2009). Distinct hippocampal and basal ganglia contributions to probabilistic learning and reversal. J Cogn Neurosci 21: 1821-1833.
56. Tieu K, (2011). A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 1: a009316.
57. Wang Y, Zhu G, Briz V, Hsu YT, Bi X, Baudry M, (2014). A molecular brake controls the magnitude of long-term potentiation. Nat Commun 5: 3051.
58. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, et al. (2005). Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8: 1069-1077.
59. Zhu G, Chen Y, Huang Y, Li Q, Behnisch T, (2011). MPTP-meditated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity. Toxicol Appl Pharmacol 254: 332-341.
60. Zhu G, Huang Y, Chen Y, Zhuang Y, Behnisch T, (2012). MPTP modulates hippocampal synaptic transmission and activity-dependent synaptic plasticity via dopamine receptors. J Neurochem 122: 582-593.
61. Zhu G, Wang X, Wu S, Li X, Li Q, (2014). Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice. Phytother Res 28: 179-186.